Bernstein Reports Pharma Could Survive Price Setting Based On Value

By John Wilkerson / May 20, 2021 at 3:11 PM
Setting prices based on what drugs are worth would hurt brand drug makers, but it is a far better policy for the industry than tying U.S. prices to those abroad, biopharmaceutical analyst firm Sanford C. Bernstein said in a recent report to investors. Widespread adoption of drug appraisals by the Institute for Clinical and Economic Review (ICER) would reduce brand drug maker revenue by about 15%, Bernstein reported, and the brand drug industry could withstand that hit. “[W]e are not...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.